For decades, cannabis has been trapped in a political purgatory, classified, vilified, and regulated as if it were a dangerous, single-molecule synthetic drug. But anyone who’s ever looked beyond the government propaganda or actually interacted with the plant knows better: cannabis is not a “drug” in the traditional pharmaceutical sense. Many of us see it as a nutraceutical, a natural, complex botanical with broad potential that belongs in the hands of the people, not the pocketbooks of pharmaceutical conglomerates.
With the DEA and FDA eyeing a possible reschedule to Schedule III, many headlines are celebrating it as “progress.” But let’s call it what it is: a half-measure that keeps cannabis chained to unnecessary federal control. If we want real reform, cannabis must be descheduled, not rescheduled.
Rescheduling to Schedule III: A Wolf in Sheep’s Lab Coat
On paper, Schedule III sounds better than Schedule I, it acknowledges “medical use” and less potential for abuse. But don’t be fooled. Rescheduling is not freedom; it’s a transfer of control from prohibitionists to bureaucrats.
Under Schedule III, cannabis would still be governed by the Controlled Substances Act (CSA), meaning the DEA stays in charge, federal oversight persists, and access remains heavily restricted.
It’s like moving cannabis from solitary confinement to a minimum-security prison. Sure, there’s a little more sunlight, but the bars are still there.
Here’s what Schedule III actually means:
Only FDA-approved, pharmaceutical-style products can be legally prescribed.
Plant-based, whole-plant cannabis remains federally restricted.
Multi-state operators and small farmers risk getting boxed out while larger pharmaceutical and biotech players position themselves to move in.
Tax code Section 280E relief applies, but at the cost of tighter regulatory oversight that could crush smaller businesses under paperwork and compliance costs.
If we’re not careful, rescheduling …
Read More
Author: Bill Levers / High Times
